Zura Bio’s (ZURA) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Zura Bio (NASDAQ:ZURA) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $5.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. Leerink Partners began coverage on Zura Bio in a research note on Monday, November 4th. They set an “outperform” rating and a $15.00 price target on the stock. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a report on Friday, October 18th. Chardan Capital dropped their price objective on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $26.00 target price on shares of Zura Bio in a research note on Thursday, September 19th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Zura Bio presently has a consensus rating of “Buy” and a consensus price target of $15.80.

Zura Bio Trading Down 7.9 %

NASDAQ ZURA opened at $2.90 on Monday. Zura Bio has a 52 week low of $2.00 and a 52 week high of $6.35. The company has a 50 day moving average price of $4.18 and a 200 day moving average price of $4.08.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). As a group, equities analysts forecast that Zura Bio will post -0.65 EPS for the current year.

Insider Buying and Selling

In related news, Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now directly owns 2,085,418 shares in the company, valued at $8,070,567.66. The trade was a 2.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 22.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC raised its stake in Zura Bio by 777.1% during the third quarter. Barclays PLC now owns 64,061 shares of the company’s stock worth $260,000 after purchasing an additional 56,757 shares during the period. Geode Capital Management LLC increased its position in shares of Zura Bio by 70.6% during the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock worth $3,706,000 after purchasing an additional 377,545 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in shares of Zura Bio in the 3rd quarter valued at approximately $2,999,000. State Street Corp lifted its holdings in shares of Zura Bio by 47.5% in the 3rd quarter. State Street Corp now owns 395,059 shares of the company’s stock worth $1,604,000 after acquiring an additional 127,300 shares during the last quarter. Finally, Braidwell LP purchased a new position in shares of Zura Bio during the 3rd quarter worth approximately $10,040,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.